J3399 Injection onase abepar-xioi treat
J-Codes
Also known as: onasemnogene abeparvovec, Zolgensma, spinal muscular atrophy gene therapy
Onasemnogene abeparvovec-xioi (Zolgensma) treatment per injection is gene therapy for spinal muscular atrophy delivery.
Clinical Context
Gene therapy for spinal muscular atrophy caused by survival motor neuron gene mutations. Single intravenous infusion delivers functional SMN gene. Prevents progression of muscle weakness in early-onset spinal muscular atrophy.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.